Notizie AIOM – anno XIV n. 607

29 Novembre 2016

EC Approves Nivolumab for Hodgkin Lymphoma

The European Commission (EC) has approved nivolumab (Opdivo) for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin (Adcetris), according to Bristol-Myers ...
Leggi tutto

29 Novembre 2016

Early Palliative Care and Its Role in Oncology: A Qualitative Study

Early integration of palliative care alongside oncology is being increasingly recommended, although the strategies and models for integration remain poorly defined. We solicited the opinions of patients and caregivers who participated in a randomized trial of early palliative ...
Leggi tutto

25 Novembre 2016

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with lung cancers. To assess the activity of cabozantinib in patients with RET-rearranged ...
Leggi tutto

25 Novembre 2016

Nuova web-app

Una web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del polmone è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...
Leggi tutto

25 Novembre 2016

CAP/ASCP/ASCO Guideline on HER2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma

As reported by Angela N. Bartley, MD, of St Joseph Mercy Hospital, Ann Arbor, and colleagues in the Journal of Clinical Oncology, the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and ASCO have released a guideline on HER2 testing ...
Leggi tutto

25 Novembre 2016

FDA Approves Daratumumab in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Multiple Myeloma

On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone, or bortezomib (Velcade) and dexamethasone, for the treatment of patients with multiple myeloma who have received ...
Leggi tutto

25 Novembre 2016

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib ...
Leggi tutto

25 Novembre 2016

Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?

The goal of re-programming the host immune system to target malignancy with durable anti-tumour clinical responses has been speculated for decades. In the last decade such speculation has been transformed into reality with unprecedented and durable responses to immune checkpoint ...
Leggi tutto

25 Novembre 2016

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer Analysis of the NSABP B-31 Trial

Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent ...
Leggi tutto

25 Novembre 2016

Ora disponibile su PubMed Central

Tutti i numeri già pubblicati nel primo volume di ESMO Open sono consultabili online e i successivi lo saranno immediatamente dopo la pubblicazione. Leggi gli articoli

LAVORIAMO CON

News

MEDICINA DI LABORATORIO, OLTRE IL 70% DELLE DECISIONI CLINICHE DIPENDE DALLE ANALISI. PRESENTATO IL PRIMO STUDIO NAZIONALE SULL’APPLICAZIONE DEL NUOVO NOMENCLATORE TARIFFARIO

TUMORI: “CNAO È CENTRO DI RIFERIMENTO MONDIALE NELL’ADROTERAPIA. A OGGI TRATTATI PIÙ DI 6.200 PAZIENTI”

MALATTIE AUTOIMMUNI: AL GIFFONI FILM FESTIVAL ARRIVA “PIÙ FORTE IO”. CON TENACIA E NUOVE TERAPIE POSSIBILE SUPERARE LE PATOLOGIE CRONICHE

L’OCULISTA: ANCHE IN ESTATE POSSIBILE FARSI OPERARE DI GLAUCOMA. PER PROTEGGERE GLI OCCHI BASTANO MASCHERINE, CAPPELLINI E OCCHIALI

MEDICINA DI LABORATORIO, I CLINICI ITALIANI RICONOSCIUTI TRA LE ECCELLENZE INTERNAZIONALI. “IL NOSTRO PAESE TRA I PROTAGONISTI DELL’EVOLUZIONE DELLA DIAGNOSTICA NEL MONDO”

TUMORE DELL’OVAIO, 1 DONNA SU 3 ASPETTA PIÙ DI UN ANNO PER LA DIAGNOSI. “NECESSARIO AUMENTARE L’ACCESSO AI CENTRI AD ALTO VOLUME, AL SUPPORTO PSICONCOLOGICO E ALL’INNOVAZIONE TERAPEUTICA”

TUMORE DEL SENO, IN ITALIA 950MILA DONNE VIVONO CON UNA DIAGNOSI. ROPI: ‘RACCOMANDATI ALMENO 150 MINUTI D’ATTIVITA’ FISICA ALLA SETTIMANA’

Notizie AIOM – anno XIV n. 607

EC Approves Nivolumab for Hodgkin Lymphoma

Early Palliative Care and Its Role in Oncology: A Qualitative Study

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

Nuova web-app

CAP/ASCP/ASCO Guideline on HER2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma

FDA Approves Daratumumab in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Multiple Myeloma

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer Analysis of the NSABP B-31 Trial

Ora disponibile su PubMed Central